In the last few years macrocyclic peptides have emerged as a better class of lead candidates for inhibition of protein-protein interactions with respect to conventional small molecules. The IRBM peptide chemistry team collaborated with the teams at Merck & co. and RaPharma to develop potent macrocyclic peptide inhibitors of PCSK9 a key regulator of plasma LDL-cholesterol.
DNA IRBM
New IRBM Contribution to the Journal of Pharmaceutical and Biomedical Analysis
IRBM researchers, led by Dr. Edith Monteagudo, have published a novel method to assess metabolism at the injection site of subcutaneously administered therapeutic peptides. Click on the link below to visit the article’s page on ScienceDirect.